• Vaccine Name: Rotavirus VP2/VP 6 Protein Vaccine
• Target Pathogen: Rotavirus
• Target Disease: Gastroenteritis
• Vaccine Ontology ID: VO_0004160
• Type: Subunit vaccine
• Status: Research
• VP2 gene engineering:
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0000143
  • Description: A detoxified version of cholera toxin, CT-E29H (Siadat-Pajouh and Cai, 2001).
• Immunization Route: Orally

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: Four-week-old BALB/c mice were vaccinated twice at Weeks 0 and 2 either orally or i.n. with 100 and 10 ug of 2/6-VLPs, respectively; each vaccine dose was formulated with 10 mg of CT-E29H. A third group of BALB/c mice (n = 4) received 2/6-VLPs with CT-E29H i.n. followed by an oral booster immunization (i.e., mixed group). Control mice in this experiment were inoculated with CT-E29H, 13 TNC, and 2/6-VLPs alone. Each mouse was inoculated i.n. with 20 uL of inoculums , 2 uL at a time into alternating nares at 1-min intervals (Siadat-Pajouh and Cai, 2001).
• Challenge Protocol: All animals were challenged by gavage with 10 SD50 of wild-type EDIM rotavirus at week 13 (BALB/c mice). The trypsin-activated challenge virus (100 uL) was administered following oral inoculation of 100 uL of 4% sodium bicarbonate solution to neutralize gastric acidity (Siadat-Pajouh and Cai, 2001).
• Efficacy: In BALB/c mice, intranasal vaccination with 2/6-VLPs and CT-E29H proved protective (PRAS 5 98.7%), in contrast to intranasal immunization with 2/6-VLPs alone (PRAS 5 39%), demonstrating the significant augmentation in protective immune responses due to CT-E29H. BALB/c mice in all three immunization groups showed nearly complete protection from the challenge. PRAS was 99.6, 98.8, and 98.8% for the oral, intranasal, and the mixed groups, respectively. The unimmunized control group shed significantly more viral antigen than the three immunized groups (Siadat-Pajouh and Cai, 2001).